Hillrom Strengthens the Centrella Smart+Bed with New Acquisition

The Chicago, IL-based company has acquired a contact-free continuous monitoring technology from EarlySense for $30 million with the potential for milestones.

Omar Ford

February 1, 2021

2 Min Read
Casimiro -stock.adobe.com

Hillrom is acquiring a contact-free continuous monitoring technology from EarlySense for $30 million with the potential for milestones. The Chicago, IL-based company said the deal is not expected to have a material impact on its fiscal 2021 financial guidance.

Hillrom has plans to integrate Ramat Gan, Israel-based EarlySense’s contact-free continuous monitoring and analytics technology into the Centrella Smart+ med-surg bed and ecosystem of connected devices.

The Centrella Smart+ bed allows for continuous monitoring of patients' heart and respiratory rates over 100 times per minute without ever touching the patient. The addition of the contact-free continuous monitoring technology would give the Centrella Smart-bed the potential to alert clinicians to potential patient deterioration events much earlier than traditional monitoring methods.

The company said it would provide EarlySense a license to the continuous monitoring, as EarlySense continues to develop next-generation artificial intelligence-based sensing technologies specifically for the remote patient care market.

"Hillrom is transforming care with highly differentiated sensing and digital communication capabilities that drive improved patient safety and ensure timely, effective clinical intervention," Hillrom President and CEO John Groetelaars said in a release. "We look forward to bringing these critical technologies to more customers around the world as we deliver on our vision of Advancing Connected Care."

Hillrom’s plan to acquire the continuous monitoring technology comes right on the heels of it announcing it would acquire Bardy Diagnostics for $375 million with the potential for milestones. The deal would give Hillrom access to the Carnation Ambulatory Monitor (CAM) patch and is set to close in 2Q21.

BardyDX’s CAM Patch was one of 16 COVID-19 innovations spotlighted by MD+DI in a special report in May of 2020. The company received CE mark for a 14-day version of the patch. The device won a nod from FDA in 2019 and a Health Canada clearance in February 2020.

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like